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Abstract
Background Efficient vaccines against hepatitis C virus (HCV) infection
are urgently needed. Vaccine development has been hampered by the lack
of suitable small animal models to reliably test the protective capacity of
immmunization.
Methods We used recombinant murine gammaherpesvirus 68 (MHV-68) as
a novel challenge virus in mice and tested the efficacy of heterologous
candidate human vaccines based on modified vaccinia virus Ankara or
adenovirus, both delivering HCV non-structural NS3 or core proteins.
Results Recombinant MHV-68 expressing NS3 (MHV-68-NS3) or core
(MHV-68-core) were constructed and characterized in vitro and in vivo. Mice
immunized with NS3-specific vector vaccines and challenged with MHV-68-
NS3 were infected but showed significantly reduced viral loads in the acute
and latent phase of infection. NS3-specific CD8+ T cells were amplified
in immunized mice after challenge with MHV-68-NS3. By contrast, we did
neither detect a reduction of viral load nor an induction of core-specific CD8+
T cells after core-specific immunization.
Conclusions Our data suggest that the challenge system using recombinant
MHV-68 is a highly suitable model to test the immunogenicity and
protective capacity of HCV candidate vaccine antigens. Using this system,
we demonstrated the usefulness of NS3-specific immunization. By contrast,
our analysis rather discarded core as a vaccine antigen. Copyright  2007
John Wiley & Sons, Ltd.
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Introduction
Hepatitis C virus (HCV) infection causes severe human disease of high preva-
lence world wide. There is no effective vaccine available and, at present,
the only relevant preclinical model is the infection of chimpanzees. Thus, for
the development of promising candidate vaccines, a suitable small animal
model system would be highly desirable. Recently, we proposed infection
with recombinant murine gammaherpesvirus 68 (MHV-68) as a novel mouse
challenge model to test the protective efficacy of heterologous vaccines based
on recombinant modified vaccinia virus Ankara (MVA) [1]. Thus, infection of
mice with recombinant MHV-68 expressing antigens of HCV could be a robust
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test system for HCV vaccines. HCV-core protein is rela-
tively conserved among HCV genotypes, and immuniza-
tions induced HCV-core specific antibody and cytotoxic
T lymphocyte (CTL) responses [2,3]. However, there is
some controvery regarding its usefulness as vaccine anti-
gen because HCV-core appears to have many regulatory
functions, being involved in the modulation of host cell
apoptosis, transcription, transformation and immune pre-
sentation [4,5]. Non-structural protein 3 (NS3) is a highly
conserved, bi-functional protein with a serine protease in
the N-terminal one-third and a RNA helicase in the C-
terminal two-thirds. Immune responses to HCV-NS3 have
been implicated in viral clearance. Numerous CTL epi-
topes have been identified in NS3 [6–8], and strong T
helper responses to NS3 have been correlated with recov-
ery from hepatitis [8] and were demonstrated to be long
lived [9].
In the present study, we established the recombi-
nant MHV-68 challenge system to assess the efficacy of
HCV-specific candidate vaccines upon delivery of HCV-
core or NS3 antigens. Importantly, the MHV-68 chal-
lenge system first demonstrated the in vivo benefit of
NS3- but not core-specific vaccination with recombinant
MVA vaccines and revealed a significant enhancement
of protective capacity when applying NS3 in a heterolo-
gous prime-boost regimen with recombinant adenovirus
and MVA.
Materials and methods
Plasmid construction
To construct the recombination plasmid pST76K-SR-
M1/M2-NS3, the 1.9-kb NS3 fragment (amino acids
1028–1658) [10] was cloned blunt end into the SmaI
site of pMCMV4 (kindly provided by Martin Messerle)
between the MCMV promoter and the polyA signal. To
obtain the recombination plasmid pST76K-SR-M1/M2-
core, the 573-bp core (amino acids 1–191) [10] fragment
was cloned into the BamHI/PstI site of pMCMV4. The
NS3- or core-expression cassettes (excised by HindIII)
were cloned blunt end into the BglII site (position 3846
of the MHV-68 genome) of the plasmid pST76K-SR
M1/M2. Thus, the NS3- or core-expression cassettes are
flanked on both sides by a homologous sequence of the
MHV-68 genome (position 2406–3846 as 5′ flank and
position 3847–6261 as 3′ flank). The following two-
step mutagenesis procedure was performed as previously
described [11,12].
Reconstitution and characterization of
recombinant MHV-68
BHK-21 cells, Ref-Cre cells, NIH3T3 cells and MC3T3
fibroblasts were used and recombinant MHV-68 were
reconstituted and characterized as previously described
[1]. Expression of NS3 and core was tested by western
blot analysis using rabbit polyclonal anti-HCV protein
antibodies (Antigenix America Inc./Bio-Trade, Vienna,
Austria; 1 : 10 000, 1 : 5000, respectively).
Generation of viral vector vaccines
MVA-NS3, MVA-core, Adeno-NS3 and
Adeno-core
HCV-1b core (amino acids 1–191) and NS3 (amino
acids 1028–1658) sequences were originally prepared
from plasmids pCMV-C980 and pCMV-N-729–3010 [10]
and expressed in recombinant MVA under transcriptional
control of vaccinia virus promoter P7.5 [13–15]. Vaccine
preparations were purified by ultracentrifugation through
sucrose, and stored in 1 mM Tris-HCl, pH 9.0 at −80 ◦C
[15]. Synthesis of recombinant HCV antigens was quality
controlled by western blot analysis (data not shown). Non-
recombinant MVA was used to immunize control animals.
Generation and characterization of vaccine preparations
based on recombinant adenovirus expressing HCV core
(Adeno-core) and NS3 (Adeno-NS3) proteins have been
previously described [16,17].
In vivo experiments
All animal experiments were in compliance with protocols
approved by the local Animal Care and Use Committee
and were performed as previously described [1]. Briefly,
C57BL/6 (B6) mice (Charles River, Sulzfeld, Germany)
were infected intranasally (i.n.) with 5 × 104 plaque
forming units (PFU) or intraperitoneally (i.p.) with
1 × 106 PFU. To determine virus titers, lungs were
harvested on day 6 after i.n. infection and spleens on day 6
after i.p. infection. For determination of spleen weight and
frequency of virus reactivation, spleens were collected on
day 17 or 21 after i.n. or i.p. infection. To assess protective
capacity of vaccines, mice were immunized i.p. with 108
infectious units (IU) MVA-WT, MVA-NS3 or MVA-core or
109 IU Ad-NS3 or Ad-core in 250 µl phosphate-buffered
saline (PBS). Mice were challenged i.n. with 5 × 104 PFU
MHV-68-WT∗, MHV-68-NS3 or MHV-68-core in 30 µl PBS
or i.p. with 106 PFU in 250 µl PBS. Lungs and spleens
were harvested as described above, and virus titers were
determined as previously described [1].
Limiting dilution reactivation assay
The frequency of cells carrying virus reactivating from
latency was determined as described previously [18].
Intracellular cytokine staining assay
Splenocytes were re-stimulated with MC3T3 fibroblasts
infected with MHV-68-WT∗, MHV-68-NS3 or MHV-68-
core. In addition, in the case of NS3, splenocytes
were re-stimulated by incubation with NS3 peptide
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LGAVQNEVTLTHPIT containing the H2-Kb restricted CTL
epitope GAVQNEITL (position 1629–1637) [19]. MC3T3
cells were infected for 1 h with a different multiplicity of
infection (MOI) of MHV-68-WT∗, MHV-68-NS3 or MHV-
68-core and grown over night at 37 ◦C. After harvest with
10 mM EDTA in PBS or medium, cells were incubated
with splenocytes of vaccinated mice for 2 h at 37 ◦C.
After adding Brefeldin A (Golgi Plug, PharMingen/Becton
Dickinson) at a final concentration of 1 µg/ml, cells were
incubated for 8 h at 37 ◦C and then kept at 4 ◦C over
night. To measure NS3-specific T-cell response, spleen
cells of vaccinated and challenged mice were incubated
with peptide at a final concentration of 1 µg/ml for 2 h,
with Brefeldin A at a final concentration of 1 µg/ml for
5 h, and then kept at 4 ◦C over night. Following steps
were performed as previously described [20].
Chromium release assay
Splenocytes of na ı¨ve B6 mice were infected with MHV-
68-NS3 or MHV-68-core (MOI = 0.1) for 1.5 h, washed,
irradiated (3000 rad) and incubated with splenocytes
from MVA-WT-, MVA-NS3-, MVA-core-, Ad-NS3/MVA-
NS3- or Ad-core/MVA-core-vaccinated mice at 37 ◦C and
5% CO2. After 5 days of culture, lytic activities of CTL
were determined in a 6-h 51Cr-release assay as previously
described [1].
Measurement of latent viral load by
quantitative real time polymerase
chain reaction (PCR)
Latent viral load in spleens of infected mice was quantified
by real-time PCR using the ABI 7300 Real Time PCR
System (Applied Biosystems, Foster City, CA, USA) as
previously described [1].
Statistical analysis
If not otherwise indicated, data were analysed by
Student’s t-test.
Results
Construction of MHV-68-NS3 and MHV-68-core and
in vitro and in vivo characterization. After generation
by BAC-technology, we analysed the genomes of the
recombinant viruses MHV-68-NS3 and MHV-68-core
by restriction enzyme analysis and Southern blot
(Figures 1A, 1B and 1C). As designed, insertion of the
2.5-kb core- or 3.8-kb NS3-coding expression cassette,
respectively, into the BglII site at nucleotide position
3846 of the MHV-68 genome [21] resulted in a shift of
the HindIII-E fragment from 6.1 kb in the parental BAC-
derived virus (= WT∗) to 8.6 kb in MHV-68-core or 9.9 kb
in MHV-68-NS3. In vitro, both MHV-68-core and MHV-68-
NS3 showed comparable growth kinetics to MHV-68-WT∗
(Figure 1D). Western blot analysis demonstrated the
ability of MHV-68-NS3 and MHV-68-core to produce
the respective proteins upon infection of NIH3T3 cells
(Figures 1E and 1F). Intranasal infection of mice with
MHV-68 results in an acute, productive infection in
the lung with viral titers reaching the peak around
day 6 post infection [22,23]. Hence, to test for lytic
replication in vivo, C57BL/6 mice were infected i.n. with
5 × 104 PFU of MHV-68-WT∗, MHV-68-NS3 or MHV-68-
core. At day 6 after infection, titration of infectious virus
from lung homogenates demonstrated that all viruses
produced very similar amounts of lytic virus (Figure 2A).
Both after i.n. and i.p. MHV-68 infection, latency is
established in the spleen and other lymphoid organs
[22]. The latent infection in the spleen is associated
with a marked splenomegaly, an increase in the number
of splenocytes and a rise in the number of latently
infected B cells which peak around 2–3 weeks post
infection [24]. B lymphocytes are the major reservoir
harboring latent MHV-68 [25], but macrophages [26],
dendritic cells [27] and lung epithelial cells [28] have
also been shown to harbor latent virus. Memory B cells
are the major reservoir for long-term latency [29–31].
Following the amplification of latency, there is both
a decrease of the splenomegaly and of the number of
latently infected splenocytes back to a basal level [22].
Multiple immune mechanisms including CD8+ T cells,
CD4+ T cells and antibodies contribute to the control
of latency and preventing recrudescence of lytic virus
[22,32]. Thus, to analyse virus latency, C57BL/6 mice
were infected i.p. with 1 × 106 PFU of MHV-68-WT∗,
MHV-68-NS3 or MHV-68-core. At day 17 after infection,
the weight of spleens from mice infected with MHV-
68-NS3 was significantly higher than the spleen weight
of naive mice but significantly lower than the spleen
weight of mice infected with MHV-68-WT∗ (Figure 2B).
By contrast, spleen weights of mice infected with MHV-
68-core or MHV-68-WT∗ were close to equal (Figure 2B).
The frequency of reactivating virus in cells in the
ex vivo reactivation assay was 1 in 14 000 splenocytes
from mice infected with MHV-68-WT∗, 1 in 49 000
splenocytes from mice infected with MHV-68-NS3 and
1 in 2000 splenocytes from mice infected with MHV-68-
core (Figure 2C). Moreover, the viral genomic load was
significantly higher in mice infected with MHV-68-core,
compared to MHV-68-WT∗ (Figure 2D). Similar results
were obtained after i.n. infection (data not shown).
Ex vivo expansion of NS3-specific, but not of core-
specific T cells, by stimulation with MHV-68-NS3 or
MHV-68-core. The use of MHV-68-NS3 infected target
cells allowed for efficient ex vivo amplification of NS3-
specific, MHC class I-restricted CD8-positive T cells
derived from MVA-NS3-vaccinated C57BL/6 mice. Only
splenocytes from MVA-NS3 immunized mice contained
CD8+ T cells (approximately 7%) being specifically
activated by MHV-68-NS3 infected targets (Figure 3A).
Notably, splenocytes from MVA-NS3 immunized mice
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Figure 1. Construction and in vitro characterization of MHV-68-NS3 and MHV-68-core. (A) Schematic map of the MHV-68 genome
with the inserted 3.8-kb NS3 and 2.5-kb core expression cassettes, respectively, indicated. (B) Ethidium bromide stained agarose
gel of HindIII-digested viral DNA. (C) Southern blot analysis of the gel shown in (B) using a DIG-labelled probe (920 bp, nucleotide
positions 2520–3440), recognizing a 6.1-kb-fragment in the parental BAC virus (= WT∗), a 9.9-kb-fragment in the MHV-68-NS3 and
a 8.6-kb-fragment in the MHV-68-core, indicated by arrows in (B) and arrowheads in (C). Marker sizes (in bp) are indicated on the
left. (D) In vitro growth curves. NIH3T3 cells were infected with a MOI of 0.1 with MHV-68-WT∗, MHV-68-NS3 or MHV-68-core. Cells
were harvested at different timepoints and titers determined on BHK-21 cells. (E) and (F) Expression of NS3 and core, respectively,
in infected fibroblasts. NIH3T3 cells were infected with MHV-68-WT∗, MHV-68-NS3 or MHV-68-core with a MOI of 1. Forty-eight
hours after infection, cells were harvested and expression of NS3 and core, respectively, was detected by western blot
were only activated with MHV-68-NS3 infected stimulator
cells but not with MHV-68-WT∗ infected stimulator cells
clearly demonstrating antigen specificity. By 51Cr release
assay, we confirmed that these activated T cells were
also functional. Splenocytes from vaccinated mice were
incubated with fibroblasts infected with MHV-68-NS3 or
MHV-68-WT∗, and only those derived from MVA-NS3
immunized mice were able to specifically lyse MHV-
68-NS3 infected fibroblasts (Figure 3B). By contrast to
NS3-specific vaccination, we were not able to demonstrate
ex vivo amplification of core-specific CD8+ T cells from
MVA-core-vaccinated C57BL/6 mice (Figures 3C and 3D).
Reduced viral loads of MHV-68-NS3 challenge virus
after vaccination with NS-3 specific vaccines. To test the
effect of vaccination with NS3 on the lytic replication of
the challenge virus MHV-68-NS3, mice were immunized
two times within 14 days with MVA-WT, MVA-NS3
or Ad-NS3/MVA-NS3. Eight weeks after the second
immunization, mice were challenged i.n. with MHV-
68-NS3, and lungs were harvested at day 6 after
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Figure 2. In vivo characterization of MHV-68-NS3 and MHV-68-core. (A) Lytic virus titers in the lungs. C57BL/6 mice were infected
i.n. with 5 × 104 PFU of MHV-68-WT∗, MHV-68-NS3 or MHV-68-core. At day 6 after infection, lungs were harvested, and virus
titers were determined from organ homogenates by plaque assay on BHK-21 cells. (B) Spleen weights, (C) ex vivo reactivation
of splenocytes and (D) viral genomic load in the spleen. C57BL/6 mice were infected i.p. with 1 × 106 PFU of MHV-68-WT∗,
MHV-68-NS3 or MHV-68-core. At day 17 after infection, spleens were harvested and the spleen weights were taken. Single
splenocyte suspensions were prepared and analysed in the ex vivo reactivation assay or used for DNA isolation for real time PCR
analysis. Data shown in (A), (B) and (D) are the means ± SD of the number of individual mice indicated with n. Data shown
in (C) are from a representative experiment. For the ex vivo reactivation assay (C), splenocytes from three mice per group were
pooled. The dashed line in (C) indicates the point of 63.2% Poisson distribution, determined by nonlinear regression, which was
used to calculate the frequency of cells reactivating lytic replication
challenge. Mice immunized with MVA-NS3 showed a
significant reduction of the lung titer compared to mice
immunized with MVA-WT. This effect was even more
pronounced when the mice were immunized with Ad-
NS3/MVA-NS3 (Figure 4A). Importantly, immunization
with Ad-NS3/MVA-NS3 did not reduce the lung titer
of the challenge virus MHV-68-core, indicating that the
observed effects are antigen-specific (compare Figure 4A
with Figure 5A, left). To determine the influence of
vaccination on the latent infection with MHV-68-NS3 as
well as on T cell immunity, we immunized C57BL/6
mice twice within 14 days with MVA-WT, MVA-NS3
or Ad-NS3/MVA-NS3. Four weeks after the second
immunization, mice were challenged i.p. with MHV-
68-NS3 and spleens were harvested at day 21 after
challenge. The frequency of reactivation was 1 in 120 000
for both the 2xMVA-WT/MHV-68-NS3 control group and
the 2xMVA-NS3/MHV-68-NS3 group. By contrast, the
mice immunized with Ad-NS3/MVA-NS3 showed a drastic
reduction in the number of ex vivo reactivating splenocytes
to an undetectable level in this assay (Figure 4B).
Consistent with these results, mice immunized with Ad-
NS3/MVA-NS3 and challenged with MHV-68-NS3 showed
a substantial increase in the number of NS3-specific,
interferon (IFN)-γ -secreting CD8+ T cells (Figure 4C). In
addition, only mice immunized with Ad-NS3/MVA-NS3
showed a significant reduction of the viral genomic load
in the spleen (Figure 4D) compared to the other groups.
Similar results were obtained using different time points
and routes of challenge infection (data not shown). By
sharp contrast to the situation with NS3 but consistent
with the failure to demonstrate ex vivo amplification of
core-specific CD8+ T cells from MVA-core-vaccinated
C57BL/6 mice (see above), vaccination with MVA-core
or Ad-core/MVA-core did not reduce viral loads in the
acute (Figure 5A) or latent phase (Figure 5B) of MHV-68-
core challenge infection. This result was independent of
the time point and route of challenge infection as tested
in additional experiments (data not shown).
Discussion
The present study aimed to test the usefulness of
recombinant MHV-68 expressing HCV candidate antigens
for evaluation of the protective capacity of HCV-specific
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Figure 3. Ex vivo expansion of NS3-specific, but not of core-specific T cells, by stimulation with MHV-68-NS3 or MHV-68-core,
respectively. (A, C) Splenocytes isolated from MVA-WT, MVA-NS3 or MVA-core immunized C57BL/6 mice were re-stimulated
in vitro with MC3T3 fibroblasts infected with MHV-68-WT∗, MHV-68-NS3 or MHV-68-core (MOI = 1) as indicated. Subsequently,
the intracellular cytokine staining assay was performed as described in the Materials and Methods. Only splenocytes from MVA-NS3
immunized mice contained CD8+ T cells being specifically activated by re-stimulation with the corresponding targets. Each symbol
represents an individual mouse. (B, D) Splenocytes isolated from naive C57BL/6 mice were infected with MHV-68-WT∗, MHV-68-NS3
or MHV-68-core (MOI = 0.1), washed, irradiated, and then used for re-stimulation of splenocytes isolated from mice vaccinated
twice with MVA-WT, MVA-NS3 or MVA-core. After 5 days of culture, the lytic activity of the resultant CTL effector cells was
determined at the indicated various effector to target cell (E/T) ratios in a 6-h 51Cr-release assay as described in the Materials and
Methods. Shown are the results from three individual mice immunized with MVA-NS3 or MVA-core, respectively (grey symbols),
and two individual mice immunized with MVA-WT (black symbols). Data are from one representative experiment
experimental vaccines. Spontaneous recovery from HCV
infection in humans is typically associated with vigorous
HCV antigen-specific T cell immune responses [33,34].
For assessment in the MHV-68 model system, we
wished to test two different HCV-specific antigens. The
NS3 protein of HCV represents a promising target for
immunization because NS3-specific CD8+ and CD4+ T
cell responses have been described as positive markers
for viral clearance both in humans and chimpanzees
[9,35–42]. Second, we chose the HCV core antigen, which
represents a viral protein that is rather well conserved in
different HCV genotypes and a potential target of cross-
reactive immune responses [2,3]. Yet, this polypeptide
has also been proposed as a potential viral modulator
of host immune defense [4]. The core protein has been
shown to bind the receptor of the complement protein
C1q, to down-regulate interleukin (IL)-12 production by
macrophages and consequently to inhibit proliferation
and IL-2/IFN-γ synthesis of T cells [43–45].
Lytic replication in vitro of recombinant MHV-68-
NS3 and MHV-68-core was indistinguishable from
MHV-68-WT∗. By contrast, in vivo, we found distinct
differences. Although lytic replication of both MHV-68-
NS3 and MHV-68-core was similar to MHV-68-WT∗,
we observed significant differences with regard to the
parameters associated with latent infection. Whereas the
spleen weight of mice infected with MHV-68-NS3 was
significantly lower than the spleen weight of mice infected
with MHV-68-WT∗, the spleen weight of mice infected
with MHV-68-core was very similar to the spleen weight of
mice infected with MHV-68-WT∗. The latent viral load was
significantly lower in mice infected with MHV-68-NS3, but
significantly higher in mice infected with MHV-68-core,
compared to MHV-68-WT∗. These data are suggestive for
the immunogenicity and potential immunomodulatory
functions of HCV-NS3 and HCV-core and further studies
are clearly required on the underlying mechanisms.
Consistent with the initial observations, we were able
to demonstrate that mice vaccinated with recombinant
vector vaccines expressing HCV-NS3, but not with recom-
binant vector vaccines expressing HCV-core, showed sig-
nificantly reduced viral loads in the acute and latent
phase of challenge infection. Furthermore, the induction
of CD8+ T cells specific for HCV-NS3 but not HCV-
core could be demonstrated. These findings suggest a
clear correlation of NS3-specific vaccine immunogenic-
ity and protective capacity against challenge infection
and are in agreement with the results obtained in a
recent T cell-inducing viral vector vaccination study in
chimpanzees [46]. That study suggested the principal
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Figure 4. Reduced viral loads in the acute and latent phase of MHV-68-NS3 challenge infection after vaccination with MVA-NS3
or Ad-NS3/MVA-NS3 (A) Lung titers after i.n. challenge with MHV-68-NS3 8 weeks after prime-boost immunization as indicated.
C57BL/6 mice were immunized twice within 14 days with MVA-WT, MVA-NS3 or Ad-NS3/MVA-NS3. Eight weeks after the second
immunization, mice were challenged i.n. with MHV-68-NS3 and lungs were harvested at day 6 after challenge. Data shown are
the mean ± SD of the number of individual mice indicated with n. (B) Ex vivo reactivation of splenocytes from mice challenged
with MHV-68-NS3 4 weeks after prime-boost immunization. C57BL/6 mice were immunized twice within 14 days with MVA-WT,
MVA-NS3 or Ad-NS3/MVA-NS3. Four weeks after the second immunization, mice were challenged i.p. with MHV-68-NS3 and spleens
were harvested at day 21 after challenge. Single splenocyte suspensions were prepared and analysed in the ex vivo reactivation
assay or used for DNA isolation for real-time PCR analysis (D). Data shown are the mean ± SEM pooled from two independent
experiments for the groups immunized with MVA-WT and MVA-NS3, and from one experiment for the group immunized with
Ad-NS3/MVA-NS3. In each experiment, splenocytes from three mice per group were pooled. The dashed line indicates the point of
63.2% Poisson distribution, determined by nonlinear regression, which was used to calculate the frequency of cells reactivating
lytic replication. To calculate significance, frequencies of reactivation events were statistically analysed by paired t-test over all cell
dilutions. The statistical significance of the difference between the group immunized with Ad-NS3/MVA-NS3 and the other groups is
p = 0.03. (C) Detection of NS3-specific, IFN-γ -secreting CD8-positive T cells by intracellular cytokine staining. C57BL/6 mice were
immunized twice within 14 days with with MVA-WT, MVA-NS3 or Ad-NS3/MVA-NS3. Four weeks after the second immunization,
mice were challenged i.p. with MHV-68-NS3 and spleens were harvested at day 21 after challenge. Single splenocyte suspensions
were prepared, stimulated with LGAVQNEVTLTHPIT peptide and analysed by intracellular cytokine staining as described in the
Materials and Methods. Each symbol represents an individual mouse. The horizontal bars indicate the mean. (D) Viral genomic
load in the spleen of mice challenged with MHV-68-NS3 4 weeks after prime-boost immunization as indicated. Data shown are the
mean ± SD of the number of individual mice indicated with n
feasibility of protective vaccination against HCV infec-
tion using non-structural antigens and demonstrated the
prominent induction of NS3-epitope specific CD8+ T cells.
In the present study, we observed a substantially enhanced
immunogenicity of the Ad-NS3/MVA-NS3 prime boost
regimen compared to a homologous MVA-NS3/MVA-NS3
prime boost. This result was anticipated given that other
heterologous prime boost immunizations (e.g. the com-
bination of influenza and MVA vector vaccines) has been
shown to result in amplification of antigen-specific CD8+
T cell responses [47]. The first inoculation of recombinant
MVA vaccine induces immune responses to MVA as well
as HCV antigens. Upon homologous MVA booster immu-
nization, it can be assumed that these responses compete
with each other for preferential re-amplification [48]. By
contrast, the heterologous Ad-NS3/MVA-NS3 prime boost
regimen allows to exclusively intensify the NS3-specific
response.
By contrast to the NS3-specific responses, we could
not demonstrate the induction of CD8+ T cells specific
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Figure 5. Vaccination with MVA-core or Ad-core/MVA-core does not reduce viral loads in the acute and latent phase of MHV-68-core
challenge infection. (A) Lung titers after intranasal challenge with MHV-68-core 8 weeks after prime-boost immunization as
indicated. C57BL/6 mice were immunized two times within 14 days with Ad-NS3/MVA-NS3 (as the control), MVA-core or
Ad-core/MVA-core. Eight weeks after the second immunization, mice were challenged i.n. with MHV-68-core and lungs were
harvested at day 6 after challenge. Data shown are the mean ± SD of the number of individual mice indicated with n. (B) Viral
genomic load in the spleen of mice challenged with MHV-68-core 4 weeks after prime-boost immunization as indicated. C57BL/6
mice were immunized twice within 14 days with Ad-NS3/MVA-NS3 (as the control), MVA-core or Ad-core/MVA-core. Four weeks
after the second immunization, mice were challenged i.p. with MHV-68-core and spleens were harvested at day 17 after challenge.
Single splenocyte suspensions were prepared and used for DNA isolation for real-time PCR analysis. Data shown are the mean ±
SD of the number of individual mice indicated with n
for HCV-core by using MC3T3 cells infected with MHV-
68-core for re-stimulation. One possibility we considered
was that the MVA-core vector used is non-immunogenic.
However, we could demonstrate core-specific CD8+ T
cells in MVA-core or MVA-1-830 (core, E1, E2, p7)
immunized BALB/c or transgenic HHD mice, with the
latter expressing human HLA-A∗0201, by using a HCV-
core specific peptide (HLA-A∗0201-restricted epitope
DLMGYIPLV; amino acids 132–140) [49] for stimulation,
thus ruling out a possible malfunction of the vector (data
not shown). Another possibility was that the sequence of
core in MVA-core is not exactly the same as the one in the
MHV-68-core. However, sequencing analysis confirmed
that both sequences are identical (data not shown). It
is possible that the mode of re-stimulation may have an
impact on the detection of core-specific CD8+ T cells.
However, in vivo, core-specific immunization did also
not provide protection against MHV-68-core challenge
infection. Thus, from our analysis of vector vaccine-
induced immune responses, the HCV-core antigen must
be considered as an extremely poor immunogen at least
in mice. This is consistent with the suppression of vaccinia
virus-specific T cell responses after infection of mice
with recombinant vaccinia virus expressing HCV-core
[50]. Thus, our data further corroborate the possible
role of core to down-regulate host T cell responses
[43–45] and to contribute to HCV-specific immune
evasion. The underlying mechanisms of this potential
viral immunomodulation clearly require more detailed
study. By contrast to the findings by Folgori et al.
[46], the vaccination of chimpanzees with an ISCOM
adjuvanted NS-3-4-5-core polyprotein T cell vaccine or
a DNA/MVA immunization delivering core-E1-E3-NS3
could not prevent chronic persistent HCV infection
[51–52], and one might speculate about a negative
impact due to core protein activity.
In summary, the present study suggests that recom-
binant MHV-68 is a highly suitable novel model to test
immunogenicity and protective capacity of HCV candidate
antigens, including specific T cell antigens. We clearly cor-
roborate the usefulness of NS3-specific immunization. By
contrast, our analysis discarded core as a vaccine antigen.
Thus, the MHV-68 challenge model should prove useful
for the evaluation of candidate vaccines not only against
HCV, but also against other persisting virus infections.
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